Biocon Pharma Limited

Biocon Pharma Limited is a wholly owned subsidiary of Biocon Limited, an Indian biopharmaceutical group headquartered at Electronic City, Bengaluru. Biocon Limited was incorporated in 1978 and has been publicly listed in India since 2004 (BSE: 532523 / NSE: BIOCON); it reports no holding company. Group scale is substantial: roughly 16,300 employees and consolidated FY2025 revenue of about ₹15,000 crore (~US$1.8 billion), per company filings and MarketScreener/Biocon disclosures. Biocon Pharma Limited itself is not separately listed.

Operations. Biocon Pharma Limited is the group's vertically integrated generic drug-product (finished dosage) arm for regulated markets, principally the US. It files and commercializes ANDAs, leveraging the parent's API manufacturing base. Named products tied to its US generics work include generic lenalidomide capsules (Revlimid), dasatinib tablets, rivaroxaban tablets, and everolimus tablets for oral suspension, spanning oncology, hematology, and cardiovascular/anticoagulant indications. The parent group's broader Generics vertical covers 60+ APIs and 75+ formulations, and a US oral-solid-dosage plant in Cranbury, New Jersey is operated by affiliate Biocon Generics Inc. (acquired from Eywa Pharma in 2023).

Litigation posture. This is an operating company, and specifically a generics manufacturer, not an NPE. The structured case data shows zero plaintiff-side cases and one defendant-side case — the profile of a company defending Hatch-Waxman/ANDA infringement claims brought by brand owners, rather than asserting patents. There is no evidence of a patent-assertion portfolio, licensing-shell structure, or plaintiff-friendly venue activity.

Notable case. The single tracked matter is Celgene Corporation v. Biocon Pharma Limited (a consolidated action with Biocon Limited and Biocon Pharma, Inc.), filed 2021-05-14 in the U.S. District Court for the District of New Jersey, docket 2:21-cv-11261, and captioned as a 35 U.S.C. § 271 ANDA patent-infringement suit. Celgene, then a Bristol Myers Squibb subsidiary, sued over Biocon's proposed generic lenalidomide (Revlimid). Biocon answered and counterclaimed, and in September 2021 the parties announced a confidential settlement. No merits determination is reflected in the sources reviewed.